BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:03 PM
 | 
Apr 03, 2009
 |  BC Extra  |  Company News

FDA posts Serdolect briefing documents

FDA posted briefing documents ahead of Tuesday's panel meeting to discuss an NDA from H. Lundbeck A/S (CSE:LUN) for Serdolect sertindole to treat schizophrenia. Lundbeck also is seeking an additional claim that Serdolect reduces the risk of suicidality in patients with schizophrenia. The agency's Psychopharmacologic Drugs Advisory Committee...

Read the full 230 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >